The effects of multiple dosing with zileuton on antigen-induced responses in sheep

M. Scuri, L. Allegra, W. M. Abraham

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a previous study, a single dose of zileuton (10 mg/kg, po) given 2 h before antigen challenge, had a minimal effect on the antigen-induced early airway response (EAR), although it was effective in blocking the late airway response (LAR). Because our previous data indicated that 5-lipoxygenase (5-LO) products contribute to the severity of the antigen-induced EAR in these animals, we hypothesized that the lack of effect of zileuton on the EAR may have had to do with inadequate tissue levels. Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR. Each sheep was used in each of the three trials (≥ 15 days apart), the order of which was randomized. For trial 1, the sheep were treated with zileuton (10 mg/kg in 0.1% methylcellulose, po) once a day for 4 days; for trial 2, the sheep were treated with zileuton (10 mg/kg, po) for 2 days; and, for trial 3, the animals were treated with vehicle (0.1% methylcellulose) for 4 days as in trial 1. In all trials, antigen challenge followed 1 h after the last treatment. In the placebo trial, antigen challenge resulted in characteristic EAR (407 ± 102%, increase over baseline) and LAR (335 ± 75%, increase over baseline). The antigen-induced effects were completely blocked by the 4-day treatment (EAR = 24 ± 3%; LAR =17 ± 3%, P < 0.05 vs. placebo). In the 2-day trial, the immediate increase in R(L) after antigen challenge was only partially blocked (EAR = 163 ± 16%, P < 0.10 vs. placebo and P < 0.05 us. 4-day trial), but the late response was completely blocked (24 ± 3%). The protection against the EAR obtained with the 4-day treatment was significantly better (P < 0.05) than that obtained with the 2-day treatment. The results of this study show that multiple dosing with the 5-LO inhibitor, zileuton, provides protection against the antigen-induced EAR as well as LAR. The effect on the EAR is dependent on the treatment time, with dosing 4 days before antigen challenge providing a more significant effect than either dosing 2 days before challenge (this study) or on the same day as antigen challenge as was seen by us previously. This effect may be related to increased tissue levels of the drug.

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalPulmonary Pharmacology and Therapeutics
Volume11
Issue number4
DOIs
StatePublished - Aug 1 1998
Externally publishedYes

Fingerprint

zileuton
Sheep
Antigens
Methylcellulose
Placebos
Tissue
Therapeutics
Arachidonate 5-Lipoxygenase
Lipoxygenase Inhibitors
Animals

Keywords

  • Animal models
  • Asthma
  • Bronchoconstriction
  • Leukotrienes
  • Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

The effects of multiple dosing with zileuton on antigen-induced responses in sheep. / Scuri, M.; Allegra, L.; Abraham, W. M.

In: Pulmonary Pharmacology and Therapeutics, Vol. 11, No. 4, 01.08.1998, p. 277-280.

Research output: Contribution to journalArticle

Scuri, M. ; Allegra, L. ; Abraham, W. M. / The effects of multiple dosing with zileuton on antigen-induced responses in sheep. In: Pulmonary Pharmacology and Therapeutics. 1998 ; Vol. 11, No. 4. pp. 277-280.
@article{ca057568a2e54768b196113be1ca0753,
title = "The effects of multiple dosing with zileuton on antigen-induced responses in sheep",
abstract = "In a previous study, a single dose of zileuton (10 mg/kg, po) given 2 h before antigen challenge, had a minimal effect on the antigen-induced early airway response (EAR), although it was effective in blocking the late airway response (LAR). Because our previous data indicated that 5-lipoxygenase (5-LO) products contribute to the severity of the antigen-induced EAR in these animals, we hypothesized that the lack of effect of zileuton on the EAR may have had to do with inadequate tissue levels. Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR. Each sheep was used in each of the three trials (≥ 15 days apart), the order of which was randomized. For trial 1, the sheep were treated with zileuton (10 mg/kg in 0.1{\%} methylcellulose, po) once a day for 4 days; for trial 2, the sheep were treated with zileuton (10 mg/kg, po) for 2 days; and, for trial 3, the animals were treated with vehicle (0.1{\%} methylcellulose) for 4 days as in trial 1. In all trials, antigen challenge followed 1 h after the last treatment. In the placebo trial, antigen challenge resulted in characteristic EAR (407 ± 102{\%}, increase over baseline) and LAR (335 ± 75{\%}, increase over baseline). The antigen-induced effects were completely blocked by the 4-day treatment (EAR = 24 ± 3{\%}; LAR =17 ± 3{\%}, P < 0.05 vs. placebo). In the 2-day trial, the immediate increase in R(L) after antigen challenge was only partially blocked (EAR = 163 ± 16{\%}, P < 0.10 vs. placebo and P < 0.05 us. 4-day trial), but the late response was completely blocked (24 ± 3{\%}). The protection against the EAR obtained with the 4-day treatment was significantly better (P < 0.05) than that obtained with the 2-day treatment. The results of this study show that multiple dosing with the 5-LO inhibitor, zileuton, provides protection against the antigen-induced EAR as well as LAR. The effect on the EAR is dependent on the treatment time, with dosing 4 days before antigen challenge providing a more significant effect than either dosing 2 days before challenge (this study) or on the same day as antigen challenge as was seen by us previously. This effect may be related to increased tissue levels of the drug.",
keywords = "Animal models, Asthma, Bronchoconstriction, Leukotrienes, Therapy",
author = "M. Scuri and L. Allegra and Abraham, {W. M.}",
year = "1998",
month = "8",
day = "1",
doi = "10.1006/pupt.1998.0149",
language = "English",
volume = "11",
pages = "277--280",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - The effects of multiple dosing with zileuton on antigen-induced responses in sheep

AU - Scuri, M.

AU - Allegra, L.

AU - Abraham, W. M.

PY - 1998/8/1

Y1 - 1998/8/1

N2 - In a previous study, a single dose of zileuton (10 mg/kg, po) given 2 h before antigen challenge, had a minimal effect on the antigen-induced early airway response (EAR), although it was effective in blocking the late airway response (LAR). Because our previous data indicated that 5-lipoxygenase (5-LO) products contribute to the severity of the antigen-induced EAR in these animals, we hypothesized that the lack of effect of zileuton on the EAR may have had to do with inadequate tissue levels. Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR. Each sheep was used in each of the three trials (≥ 15 days apart), the order of which was randomized. For trial 1, the sheep were treated with zileuton (10 mg/kg in 0.1% methylcellulose, po) once a day for 4 days; for trial 2, the sheep were treated with zileuton (10 mg/kg, po) for 2 days; and, for trial 3, the animals were treated with vehicle (0.1% methylcellulose) for 4 days as in trial 1. In all trials, antigen challenge followed 1 h after the last treatment. In the placebo trial, antigen challenge resulted in characteristic EAR (407 ± 102%, increase over baseline) and LAR (335 ± 75%, increase over baseline). The antigen-induced effects were completely blocked by the 4-day treatment (EAR = 24 ± 3%; LAR =17 ± 3%, P < 0.05 vs. placebo). In the 2-day trial, the immediate increase in R(L) after antigen challenge was only partially blocked (EAR = 163 ± 16%, P < 0.10 vs. placebo and P < 0.05 us. 4-day trial), but the late response was completely blocked (24 ± 3%). The protection against the EAR obtained with the 4-day treatment was significantly better (P < 0.05) than that obtained with the 2-day treatment. The results of this study show that multiple dosing with the 5-LO inhibitor, zileuton, provides protection against the antigen-induced EAR as well as LAR. The effect on the EAR is dependent on the treatment time, with dosing 4 days before antigen challenge providing a more significant effect than either dosing 2 days before challenge (this study) or on the same day as antigen challenge as was seen by us previously. This effect may be related to increased tissue levels of the drug.

AB - In a previous study, a single dose of zileuton (10 mg/kg, po) given 2 h before antigen challenge, had a minimal effect on the antigen-induced early airway response (EAR), although it was effective in blocking the late airway response (LAR). Because our previous data indicated that 5-lipoxygenase (5-LO) products contribute to the severity of the antigen-induced EAR in these animals, we hypothesized that the lack of effect of zileuton on the EAR may have had to do with inadequate tissue levels. Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR. Each sheep was used in each of the three trials (≥ 15 days apart), the order of which was randomized. For trial 1, the sheep were treated with zileuton (10 mg/kg in 0.1% methylcellulose, po) once a day for 4 days; for trial 2, the sheep were treated with zileuton (10 mg/kg, po) for 2 days; and, for trial 3, the animals were treated with vehicle (0.1% methylcellulose) for 4 days as in trial 1. In all trials, antigen challenge followed 1 h after the last treatment. In the placebo trial, antigen challenge resulted in characteristic EAR (407 ± 102%, increase over baseline) and LAR (335 ± 75%, increase over baseline). The antigen-induced effects were completely blocked by the 4-day treatment (EAR = 24 ± 3%; LAR =17 ± 3%, P < 0.05 vs. placebo). In the 2-day trial, the immediate increase in R(L) after antigen challenge was only partially blocked (EAR = 163 ± 16%, P < 0.10 vs. placebo and P < 0.05 us. 4-day trial), but the late response was completely blocked (24 ± 3%). The protection against the EAR obtained with the 4-day treatment was significantly better (P < 0.05) than that obtained with the 2-day treatment. The results of this study show that multiple dosing with the 5-LO inhibitor, zileuton, provides protection against the antigen-induced EAR as well as LAR. The effect on the EAR is dependent on the treatment time, with dosing 4 days before antigen challenge providing a more significant effect than either dosing 2 days before challenge (this study) or on the same day as antigen challenge as was seen by us previously. This effect may be related to increased tissue levels of the drug.

KW - Animal models

KW - Asthma

KW - Bronchoconstriction

KW - Leukotrienes

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0032148073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032148073&partnerID=8YFLogxK

U2 - 10.1006/pupt.1998.0149

DO - 10.1006/pupt.1998.0149

M3 - Article

VL - 11

SP - 277

EP - 280

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 4

ER -